Welcome to our dedicated news page for Cidara Therapeutics (Ticker: CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Therapeutics.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cidara Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cidara Therapeutics's position in the market.
Rhea-AI Summary
Cidara Therapeutics announced data presentations at ESCMID 2024 on CD388, highlighting Phase 1 and Phase 2a clinical data. The Phase 2a study showed CD388 was well-tolerated with significant antiviral effects in healthy volunteers challenged with influenza. The Phase 1 study demonstrated an extended half-life of 6-8 weeks, indicating potential for seasonal influenza prevention.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
-
Rhea-AI Summary
Cidara Therapeutics reacquires global development and commercial rights to CD388 and announces a private placement financing of $240 million. The financing, led by RA Capital Management, aims to fund the Phase 2b clinical trial of CD388, an antiviral drug for influenza A and B. The company plans to develop CD388 as a universal preventative against seasonal and pandemic influenza. Johnson & Johnson has transferred exclusive rights to CD388 back to Cidara in exchange for an $85 million upfront payment and potential milestone payments. The private placement will support the development of CD388 through Phase 2b and beyond, with a focus on providing long-acting, universal protection against all forms of influenza. The company is set to host a business strategy update conference call and webcast to discuss the recent developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.78%
Tags
-
Rhea-AI Summary
Cidara Therapeutics announced the divestiture of rezafungin to Mundipharma to focus on advancing the Cloudbreak DFC pipeline. The transaction will provide an estimated $128 million in cost savings over the patent life of rezafungin, enabling Cidara to focus on advancing its Cloudbreak development programs, including an IND filing for its lead oncology candidate, CBO421. Mundipharma will now hold commercial rights to rezafungin outside the U.S. and Japan, with ongoing obligations related to the ReSPECT Phase 3 clinical trial and regulatory requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.78%
Tags
Rhea-AI Summary
Cidara Therapeutics, Inc. reported financial results for Q4 and full year 2023, highlighted key achievements in their Cloudbreak® platform and REZZAYO® program, including approvals in the EU and UK. The company presented new data at various medical meetings and completed enrollment in a Phase 3 trial in China. Revenue increased, cash reserves grew, and net losses decreased compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
-
Rhea-AI Summary
Cidara Therapeutics, a biotechnology company, received a delinquency notice from Nasdaq for failing to file its Annual Report on Form 10-K. The company plans to submit its compliance plan and has implemented a 1-for-20 reverse stock split to maintain its listing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
-
Rhea-AI Summary
Cidara Therapeutics, a biotechnology company, announced a 1-for-20 reverse stock split of its common stock. The reverse split will be effective on April 23, 2024, with trading on a split-adjusted basis starting on April 24, 2024. This decision was made following a stockholder vote and board approval to enhance the stock's value and reduce the number of outstanding shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.54%
Tags
Rhea-AI Summary
Cidara Therapeutics, Inc. (CDTX) announced promising preclinical data on its drug-Fc conjugate (DFC) immunotherapies at the AACR Annual Meeting. The multispecific CD73/PD-1 DFC showed improved tumor reduction over PD-1 monotherapy, CCR5-targeting DFC demonstrated efficacy in colorectal cancer, and CBO421 outperformed oleclumab in triple-negative breast cancer cell lines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.41%
Tags
-
Rhea-AI Summary
Cidara Therapeutics, Inc. to present preclinical data on drug-Fc conjugate candidates at AACR Annual Meeting, including CD73/PD-1, CCR5, and CBO421 DFCs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
-
News
Rhea-AI Summary
Cidara Therapeutics, Inc. (CDTX) receives an $11.14 million milestone payment from Mundipharma following the European approval of REZZAYO™ for the treatment of invasive candidiasis. The approval was based on positive results from the ReSTORE Phase III clinical trial, demonstrating statistical non-inferiority to the standard of care. Cidara plans to advance its Cloudbreak platform for the development of targeted immunotherapies, with a focus on cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
Rhea-AI Summary
Cidara Therapeutics, Inc. (Nasdaq: CDTX) announces that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has approved REZZAYO (rezafungin acetate) for the treatment of invasive candidiasis in adults, expanding treatment options for patients globally. The approval follows positive results from the ReSTORE Phase III clinical trial, demonstrating statistical non-inferiority for weekly-dosed rezafungin compared to the standard of care. Cidara has partnered with Mundipharma, entitled to receive a $2.8 million milestone payment for the MHRA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
Cidara Therapeutics, Inc.
Nasdaq:CDTX
CDTX Rankings
CDTX Stock Data
56.22M
76.81M
7.53%
30.63%
0.22%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
SAN DIEGO
About CDTX
cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.